CN103655552A - Application of Manzamenone O in pancreas cancer treatment medicines - Google Patents
Application of Manzamenone O in pancreas cancer treatment medicines Download PDFInfo
- Publication number
- CN103655552A CN103655552A CN201310643422.6A CN201310643422A CN103655552A CN 103655552 A CN103655552 A CN 103655552A CN 201310643422 A CN201310643422 A CN 201310643422A CN 103655552 A CN103655552 A CN 103655552A
- Authority
- CN
- China
- Prior art keywords
- manzamenone
- pancreas cancer
- medicines
- cancer treatment
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses an application of Manzamenone O in pancreas cancer treatment medicines, and belongs to the technical field of new uses of medicines. An in-vitro MTT antitumor activity evaluation result shows that the Manzamenone O has a substantial inhibition effect on the growth of human pancreas cancer cell strains PANC-1 and BXPC-3, so the Manzamenone O can be used for preparing pancreas cancer resistance medicines, and has a good exploitation application prospect. The use of the Manzamenone O in the preparation of the pancreas cancer treatment medicines is disclosed for the first time. The Manzamenone O has a strong inhibition activity against pancreas cancer cells, and has a substantial progress.
Description
Technical field
The present invention relates to the new purposes of compound Manzamenone O, relate in particular to the application of Manzamenone O in preparation treatment cancer of pancreas medicine.
Background technology
Cancer is to one of disease of human life's health hazard maximum, has a large amount of people to die from cancer every year.The research and development of cancer therapy drug are the focuses of study of pharmacy always.In antitumor drug, have 74% to be natural product or derivatives thereof, if paclitaxel and derivant thereof are exactly the reasonable antitumor drug of effect clinically at present.Therefore, from natural product, find anticancer compound or lead compound has great importance.
The compound Manzamenone O the present invention relates to is one and within 2013, delivers (Naonobu Tanaka, et al., Manzamenone O, New Trimeric Fatty Acid Derivative from a Marine Sponge Plakortis sp.Organic Letters, 2013, 15 (10): 2518 – 2521.) noval chemical compound, this compound has brand-new framework types, current purposes is found its antimicrobial (Naonobu Tanaka, et al., Manzamenone O, New Trimeric Fatty Acid Derivative from a Marine Sponge Plakortis sp.Organic Letters, 2013, 15 (10): 2518 – 2521.), the purposes of the Manzamenone O the present invention relates in preparation treatment cancer of pancreas medicine belongs to open first.
Summary of the invention
The object of the invention is to, according to not finding that it has the present situation of the report of anti-cancer of pancreas activity in existing Manzamenone O research, provides the application of Manzamenone O in the anti-cancer of pancreas medicine of preparation.
Described compound Manzamenone O structure is as shown in formula I:
The present invention finds by the evaluation of external MTT anti-tumor activity, Manzamenone O also has significant inhibitory action to the growth of human pancreas cancer cell strain PANC-1 and BXPC-3, and the IC50 value that suppresses this 2 strain Growth of Cells is respectively 1.84 ± 0.68 μ M and 1.36 ± 0.28 μ M.Therefore, Manzamenone O can, for the preparation of anti-cancer of pancreas medicine, have good development prospect.
Purposes for the Manzamenone O the present invention relates in preparation treatment cancer of pancreas medicine belongs to open first, because framework types belongs to brand-new framework types, and its inhibition for pancreatic cancer cell is active strong, possess outstanding substantive distinguishing features, the control for cancer of pancreas simultaneously obviously has significant progress.
The specific embodiment
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subject to any restriction of specific embodiment, but be limited by claim.
The preparation method of compound Manzamenone O involved in the present invention is referring to document (Naonobu Tanaka, et al., Manzamenone O, New Trimeric Fatty Acid Derivative from a Marine Sponge Plakortis sp.Organic Letters, 2013,15 (10): 2518 – 2521.), prepare according to the method described above compound Manzamenone O.
Embodiment 1: the preparation of compound Manzamenone O tablet involved in the present invention:
Get 5 and digest compound Manzamenone O, add 195 grams, dextrin, mix, conventional tabletting is made 1000.
Embodiment 2: the preparation of compound Manzamenone O capsule involved in the present invention:
Get 5 and digest compound Manzamenone O, add 195 grams of starch, mix, encapsulatedly make 1000.
Below by pharmacodynamic experiment, further illustrate its pharmaceutically active.
Experimental example: adopt the growth inhibited effect of mtt assay assessing compound Manzamenone O to human pancreas cancer cell strain
1. method: the cell in growth logarithmic (log) phase: human pancreas cancer cell strain PANC-1 and BXPC-3(buy from Chinese Academy of Sciences's cell bank) with 1.5 * 10
4concentration kind is in 96 orifice plates.After cell culture 24h is adherent, suck original culture medium.Test is divided into blank group, drug treating group.Blank group is changed 1640 culture medium containing 10% hyclone; It is 100 μ M that drug treating group is changed containing concentration, 50 μ M, 10 μ M, 1 μ M, 0.1 μ M, the culture medium of the Manzamenone O of 0.01 μ M and 0.001 μ M.Cultivate after 48h, add the MTT of concentration 5mg/mL, continue to be put in CO
2incubator is cultivated 4h, then along culture fluid top, suck 100 μ L supernatants, add 100 μ L DMSO, 10min is placed in dark place, utilize microplate reader (Sunrise company product) to measure light absorption value (wavelength 570nm), and calculating cell survival situation according to light absorption value, 6 repeating holes are established in each processing.Cell survival rate (%)=Δ OD drug treating/Δ OD blank * 100.
2. result: Manzamenone O has significant inhibitory action to the growth of human pancreas cancer cell strain PANC-1 and BXPC-3.The IC50 value that this compound suppresses human pancreas cancer cell strain PANC-1 and BXPC-3 growth is respectively 1.84 ± 0.68 μ M and 1.36 ± 0.28 μ M.
By above-described embodiment, shown, Manzamenone O of the present invention has good inhibitory action to the growth of human pancreas cancer cell strain PANC-1 and BXPC-3.Prove thus, it is active that Manzamenone O of the present invention has anti-cancer of pancreas, can be for the preparation of anti-cancer of pancreas medicine.
Claims (1)
- The application of 1.Manzamenone O in treatment cancer of pancreas medicine, described compound Manzamenone O structure is as shown in formula I:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310643422.6A CN103655552B (en) | 2013-12-04 | 2013-12-04 | Application of Manzamenone O in pancreas cancer treatment medicines |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310643422.6A CN103655552B (en) | 2013-12-04 | 2013-12-04 | Application of Manzamenone O in pancreas cancer treatment medicines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103655552A true CN103655552A (en) | 2014-03-26 |
| CN103655552B CN103655552B (en) | 2015-05-06 |
Family
ID=50295115
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310643422.6A Expired - Fee Related CN103655552B (en) | 2013-12-04 | 2013-12-04 | Application of Manzamenone O in pancreas cancer treatment medicines |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103655552B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT201700078586A1 (en) * | 2017-07-13 | 2019-01-13 | Univ Della Calabria | 6,6a-dihydrofuro [3,2-b] furan-2- (5H) onyx derivatives, their preparation and use in the treatment of tumors |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102861050A (en) * | 2012-10-27 | 2013-01-09 | 吴俊华 | Application of Houttuynoid A in medicine for treating pancreatic cancer |
| CN102885809A (en) * | 2012-10-25 | 2013-01-23 | 南京大学 | Application of Aphanamixoid A in medicament for treating pancreatic cancer |
| CN103251638A (en) * | 2013-06-03 | 2013-08-21 | 南京正亮医药科技有限公司 | Application of Polyflavanostilbene A in preparing medicine for treating pancreatic cancer |
-
2013
- 2013-12-04 CN CN201310643422.6A patent/CN103655552B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102885809A (en) * | 2012-10-25 | 2013-01-23 | 南京大学 | Application of Aphanamixoid A in medicament for treating pancreatic cancer |
| CN102861050A (en) * | 2012-10-27 | 2013-01-09 | 吴俊华 | Application of Houttuynoid A in medicine for treating pancreatic cancer |
| CN103251638A (en) * | 2013-06-03 | 2013-08-21 | 南京正亮医药科技有限公司 | Application of Polyflavanostilbene A in preparing medicine for treating pancreatic cancer |
Non-Patent Citations (1)
| Title |
|---|
| NAONOBU TANAKA等: "Manzamenone O, New Trimeric Fatty Acid Derivative from a Marine Sponge Plakortis sp.", 《ORGANIC LETTERS》, vol. 15, no. 10, 7 May 2013 (2013-05-07), pages 2518 - 2521 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT201700078586A1 (en) * | 2017-07-13 | 2019-01-13 | Univ Della Calabria | 6,6a-dihydrofuro [3,2-b] furan-2- (5H) onyx derivatives, their preparation and use in the treatment of tumors |
| EP3428169A1 (en) * | 2017-07-13 | 2019-01-16 | Universita' Della Calabria | 6,6a-dihydro furo[3,2-b]furan-2-(5h)one derivatives, their preparation and use for treating tumors |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103655552B (en) | 2015-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105250250A (en) | Application of Nootkatone in preparation of medicine for treating nasopharyngeal carcinoma | |
| CN103655552B (en) | Application of Manzamenone O in pancreas cancer treatment medicines | |
| CN103405407B (en) | Application of compound in preparation of medicines for treating pancreatic cancer | |
| CN105456243A (en) | Application of Flabelliferin B in preparing medicine for treating nasopharynx cancer | |
| CN103638016B (en) | Application of Manzamenone O in rectal cancer treatment drugs | |
| CN103432111A (en) | Application of compound to preparation of drug for treating rectal cancer | |
| CN102872010B (en) | Application of Aphanamixoid A in drugs for treating ovarian cancer | |
| CN103316008A (en) | Application of Aspeverin in preparation of medicine for treating rectal cancer | |
| CN102872142B (en) | Application of Houttuynoid D in drug for treating ovarian cancer | |
| CN103127091A (en) | Application of Aphanamixoid A in medicines curing colorectal cancer | |
| CN105412080A (en) | Application of Penicillactones B in preparation of bile duct cancer treatment drug | |
| CN105456262A (en) | Application of Melodinine E in preparing medicine for treating endometrial cancer | |
| CN105395536A (en) | Application of Flabelliferin A in preparation of drugs treating ileocecal cancer | |
| CN105456249A (en) | Application of Spirooliganone A to preparation of medicine for treating rectal cancer | |
| CN105380934A (en) | Application of Lycojaponicumins C in preparing drug for treating tongue cancer | |
| CN105456259A (en) | Application of Penibruguieramine A in preparing medicine for treating bladder cancer | |
| CN105287520A (en) | Application of Nagelamides Z in preparation of biliary duct cancer treating medicine | |
| CN103462952A (en) | Application of Nardoaristolones A in preparation of medicaments for treating ovarian cancer | |
| CN103463017A (en) | Application of Lycojaponicumin B in preparation of medicines for treating pancreatic cancer | |
| CN103463066A (en) | Application of Lycojaponicumin C in preparation of medicines for treating ovarian cancer | |
| CN103316011A (en) | Application of Aspeverin in preparation of medicine for treating skin cancer | |
| CN103479632A (en) | Application of Lycojaponicumin B in preparation of drugs for treating cervical carcinoma | |
| CN103520178A (en) | Application of compound in preparation of medicine for treating ovarian cancer | |
| CN103463058A (en) | Application of Lycojaponicumin A in medicaments for treating bile duct cancer | |
| CN103463032A (en) | Application of Lycojaponicumin A in medicine for treating pancreatic cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: BINZHOU MEDICAL COLLEGE Free format text: FORMER OWNER: CHANGZHOU COLLECTION MEDICAL INSTRUMENT CO., LTD. Effective date: 20150408 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent of invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Cheng Mei Inventor after: Wu Yulong Inventor after: Zhao Dongmei Inventor after: Ni Tianhui Inventor after: Diao Huiling Inventor after: Du Zhenzhen Inventor before: Chen Jun |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 213000 CHANGZHOU, JIANGSU PROVINCE TO: 264003 YANTAI, SHANDONG PROVINCE Free format text: CORRECT: INVENTOR; FROM: CHEN JUN TO: CHENG MEI WU YULONG ZHAO DONGMEI NI TIANHUI DIAO HUILING DU ZHENZHEN |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20150408 Address after: Laishan District of Shandong city of Yantai province Guanhai road 264003 No. 346 Applicant after: Binzhou Medical University Address before: 213000 West -256-1, building 4, West Taihu international wisdom garden, Wujin Economic Development Zone, Jiangsu, Changzhou Applicant before: CHANGZHOU KELIXIN MEDICAL DEVICES CO., LTD. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150506 Termination date: 20151204 |
|
| EXPY | Termination of patent right or utility model |